February 2026 Options Now Available For Teradyne (TER)

Teradyne (TER) is highlighted as an options income opportunity at a spot price of $195.56: selling the $192.50 put (bid $11.80) sets an effective share cost basis of $180.70 and is ~2% OTM with a 59% probability of expiring worthless, implying a 6.13% cash return (50.85% annualized) on the cash commitment. Alternatively, selling a covered $200 call (bid $13.20) against shares would yield a 9.02% total return if called at the February 2026 expiry, with a 48% chance of expiring worthless and a 6.75% premium boost (55.99% annualized). Implied volatility on both contracts is ~60% versus a trailing 12-month realized volatility of 58%.

Analysis

Market structure: The option quotes (TER $195.56, 192.50 put bid $11.80, 200 call bid $13.20) imply a market-implied yield-to-expiration of ~50–56% annualized and IV ≈60% vs realized ~58%, signaling supply/demand for near-term volatility rather than a structural dislocation. Winners: income/option sellers and long-term buyers willing to be assigned at $180.70 basis; losers: directional longs that want unlimited upside (covered-call sellers cap gains at $200). Cross-asset impact is minimal but heavy option selling could slightly compress TER option skew and produce transient hedging flows in futures and SMH/semicap ETFs.

Risk assessment: Tail risks include a semiconductor capex collapse or export-control shock that could drop TER >30% (low-probability, high-impact); operational risks include large customer deferrals in one quarter. Immediate (days) risk is gamma/execution risk around order flows or an earnings release; short-term (weeks–months) risk centers on assignment and cash needs if puts are exercised; long-term depends on robotics/automation adoption and semi equipment cycles. Hidden dependency: cash-secured put sellers must reserve full capital (~$19,250 per contract) and face concentration if assigned.

Trade implications: Direct play — sell 1–3 cash-secured 192.50 puts per $100k notional if comfortable owning TER at $180.70 (target IRR 6.1% for expiration Feb 2026; roll or close if price < $170). Alternative: buy 100–200 shares TER and write Feb26 $200 calls, size 1–3% position, set trailing stop -18% and take-profit +25%. Options strategy: prefer put-credit spreads (sell 192.5 / buy 170) to cap tail risk and collect ~3–4% net premium; consider collar if assigned.

Contrarian angles: Consensus treats these yields as ‘income’ only — market may be underweight durable robot/ATE upside outside the semiconductor cycle; if TER prints two consecutive beats (order book growth >10% q/q), covered-call sellers will be materially undercompensated. Reaction appears neither extreme; mispricing exists in tail risk (unprotected short-put collectives). Historical analog: 2016–17 capex trough recoveries show 30–60% upside exists within 6–18 months, so buy-write entry with defined downside protection is preferred to naked exposure.

Key Decisions for Investors

• Sell cash-secured TER Feb 2026 $192.50 puts sized to 1–3% of portfolio (reserve ~$19,250 per contract) to achieve ~6.13% yield to expiry; immediately hedge with a buy-$170 put to limit downside below $170 if unwilling to hold large concentrated exposure.
• Establish a 2% long position in TER (buy shares) and sell Feb 2026 $200 covered calls against all shares; set a stop-loss at -18% and take-profit at +25%, roll calls out/ up if share price rises >10% before expiration.
• If preferring defined-risk options only, sell a put credit spread: sell TER Feb26 $192.50 / buy $170; target net credit ≈3–4% of strike width and close if spread value widens >50% or TER < $180.
• Relative-value: Long TER vs short SMH equal notional (size 1–2% net long TER exposure) to isolate company-specific upside from broader cyclical semiconductor weakness; unwind if SMH outperforms TER by >8% over 30 days.
• Avoid naked short calls or uncollateralized put selling; monitor order-book/earnings and export-control headlines over next 30–90 days as catalysts—reduce net exposure by 50% if TER order-book misses guidance or IV jumps >15 pts from current 60%.